Immunotherapy prospects for acute myeloid leukaemia

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Acute myeloid leukemia (AML) frequently relapses post-chemotherapy, necessitating novel therapeutic strategies.
• Residual leukemia cells demonstrate susceptibility to immune cell attack (T cells and NK cells), supporting immune-based interventions.
• Current relapse prevention includes chemotherapy, stem cell transplantation, and immunotherapy.

Purpose of the Study:

• To review the immunological characteristics of AML at diagnosis and remission.
• To summarize the current landscape of immunotherapy for AML.
• To explore combination strategies for achieving a definitive cure for AML.

Main Methods:

• Review of existing literature on AML immunology and immunotherapy.
• Analysis of current therapeutic approaches, including cell-based therapies, vaccines, and immunomodulatory agents.
• Discussion of strategies combining immunotherapy with other treatments.

Main Results:

• AML exhibits specific immunological features at presentation and during remission.
• Various immunotherapy modalities are available, including stem cell transplantation, adoptive cell transfer (T cells, NK cells), and vaccination (leukemia cells, dendritic cells, peptides, DNA).
• Cytokines, antibodies, and immunomodulatory agents are also utilized in AML immunotherapy.

Conclusions:

• Immunotherapy holds significant potential for controlling residual AML and preventing relapse.
• Combination approaches integrating immunotherapy with conventional treatments are crucial for achieving leukemia cure.
• Further research into AML's immunological aspects and novel immunotherapy strategies is warranted.